HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Jan.27) - Surgical Robots New Policy, COVID-19 Update, Policy Vacuum Period

I-Mab (IMAB.US) - An "Entertaining Bet": To Be a Dark Horse or to Fail Completely

China Shineway Pharmaceutical (2877.HK) - Some Points Worth the Attention

Presentation for Webinar: China Healthcare - Outlook and Opportunities in 2023

Identify New Directions of China Healthcare in 2023 – Major Changes In Highest Level Policy Document

MicroPort NeuroTech (2172.HK) 22H1 - Advantages Deserve Recognition, but with Overvaluation Risk

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

<ul>
<li>The spring coil centralized procurement of neuro-interventional consumables in 21 provinces led by Jilin is about to start. The result may be unexpected, which could cause uncertainty to NeuroTech's performance.</li>
<li>The promotion of import substitution in the field of neuro-intervention has not been as smooth as expected. If foreign brands win the bid, doctors would give priority to imported products.</li>
<li>Since NeuroTech is in leading position among domestic peers and has core R&amp;D capabilities in this industry, we think it still has investment value. The valuation is in comfortable range.</li>
</ul>


The spring coil centralized procurement of neuro-interventional consumables in 21 provinces led by Jilin is about to start. The result may be unexpected, which could cause uncertainty to NeuroTech's performance.
The promotion of import substitution in the field of neuro-intervention has not been as smooth as expected. If foreign brands win the bid, doctors would give priority to imported products.
Since NeuroTech is in leading position among domestic peers and has core R&amp;D capabilities in this industry, we think it still has investment value. The valuation is in comfortable range.


MicroPort NeuroTech (2172.HK) - The Potential Risks Behind the Positive Profit Alert